Hypertrophic cardiomyopathy: The need for randomized trials
Key result
Hypertrophic cardiomyopathy research currently lacks large randomized trials, with past pharmacological studies enrolling only about 2,000 patients in mostly small, non-randomized cohorts.
Population
Individuals with hypertrophic cardiomyopathy (HCM)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Management of hypertrophic cardiomyopathy should remain cautious due to weak evidence; leaves open the need for large international randomized trials.
Structured PICO
P
Population
Individuals with hypertrophic cardiomyopathy (HCM)
Highlights the critical lack of randomized pharmacological trials in hypertrophic cardiomyopathy and advocates for international collaboration to identify effective treatments.
Cite This Study
Olivotto et al. (2013) conducted a review in Hypertrophic cardiomyopathy (HCM). Hypertrophic cardiomyopathy research currently lacks large randomized trials, with past pharmacological studies enrolling only about 2,000 patients in mostly small, non-randomized cohorts.